Bristol-Myers Squibb (NYSE:BMY) Holdings Decreased by Kahn Brothers Group Inc.

Kahn Brothers Group Inc. lowered its stake in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 16.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 690,252 shares of the biopharmaceutical company's stock after selling 135,856 shares during the period. Bristol-Myers Squibb makes up 8.4% of Kahn Brothers Group Inc.'s investment portfolio, making the stock its 4th biggest holding. Kahn Brothers Group Inc.'s holdings in Bristol-Myers Squibb were worth $39,041,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in BMY. Truist Financial Corp boosted its stake in shares of Bristol-Myers Squibb by 3.9% during the 4th quarter. Truist Financial Corp now owns 1,597,150 shares of the biopharmaceutical company's stock valued at $90,335,000 after purchasing an additional 60,365 shares in the last quarter. Contravisory Investment Management Inc. purchased a new position in shares of Bristol-Myers Squibb during the fourth quarter valued at approximately $488,000. Decker Retirement Planning Inc. purchased a new position in shares of Bristol-Myers Squibb during the fourth quarter valued at approximately $474,000. Corundum Group Inc. increased its holdings in Bristol-Myers Squibb by 67.8% during the fourth quarter. Corundum Group Inc. now owns 43,534 shares of the biopharmaceutical company's stock valued at $2,462,000 after buying an additional 17,596 shares during the last quarter. Finally, High Net Worth Advisory Group LLC increased its holdings in Bristol-Myers Squibb by 42.2% during the fourth quarter. High Net Worth Advisory Group LLC now owns 16,974 shares of the biopharmaceutical company's stock valued at $960,000 after buying an additional 5,040 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on BMY shares. The Goldman Sachs Group reiterated a "neutral" rating and issued a $55.00 price target (down from $67.00) on shares of Bristol-Myers Squibb in a research report on Tuesday, April 8th. Cantor Fitzgerald reissued a "neutral" rating and issued a $55.00 target price on shares of Bristol-Myers Squibb in a research note on Tuesday, April 22nd. Argus raised shares of Bristol-Myers Squibb to a "hold" rating in a research note on Friday, April 25th. William Blair reaffirmed a "market perform" rating on shares of Bristol-Myers Squibb in a research note on Friday, April 25th. Finally, UBS Group cut their price objective on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a research report on Friday, April 11th. Two equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have given a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $58.00.

Bristol-Myers Squibb Stock Performance

Shares of BMY stock traded down $2.53 during trading on Wednesday, reaching $44.06. The company had a trading volume of 21,892,029 shares, compared to its average volume of 13,202,084. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15. The firm's 50 day simple moving average is $53.69 and its two-hundred day simple moving average is $56.06. The company has a market capitalization of $89.67 billion, a PE ratio of -9.97, a PEG ratio of 2.07 and a beta of 0.39. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $63.33.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, beating the consensus estimate of $1.50 by $0.30. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The business had revenue of $11.20 billion for the quarter, compared to analyst estimates of $10.77 billion. During the same quarter in the previous year, the firm earned ($4.40) EPS. Bristol-Myers Squibb's quarterly revenue was down 5.6% on a year-over-year basis. Sell-side analysts forecast that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

Bristol-Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, May 1st. Investors of record on Friday, April 4th were given a dividend of $0.62 per share. The ex-dividend date of this dividend was Friday, April 4th. This represents a $2.48 annualized dividend and a yield of 5.63%. Bristol-Myers Squibb's dividend payout ratio (DPR) is presently 92.88%.

Insider Activity at Bristol-Myers Squibb

In related news, EVP Samit Hirawat acquired 1,823 shares of the business's stock in a transaction that occurred on Friday, February 14th. The shares were bought at an average cost of $54.84 per share, with a total value of $99,973.32. Following the completion of the purchase, the executive vice president now directly owns 63,932 shares in the company, valued at $3,506,030.88. The trade was a 2.94% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. Insiders own 0.09% of the company's stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.